Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA DTC Study Aims To Fool Consumers, But Not Doctors, In Use Of Fictitious Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Study examining design of print advertisements will be straightforward with doctors that a fictitious drug is being presented, while the wording for consumers will be ambiguous.

You may also be interested in...



DDMAC's Creative Minds Generate Fictitious Drug Names

DDMAC's Creative Minds Generate Fictitious Drug Names

FDA's Advertising Studies Expand To Internet Spots, Disease Awareness

FDA is continuing to start new studies on the format of advertising even as it prepares to release the results from previous research. While the steady drip of studies gives industry continuing opportunity to provide feedback to the agency's Division of Drug Marketing, Advertising and Communications, it also means that the findings that FDA makes, particularly on the impact of qualitative language, may be superseded by further research.

Related Content

Topics

UsernamePublicRestriction

Register

PS071649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel